Jay Venkatesan, Angion CEO
July 26, 2022 07:20 AM EDT
R&D

Fol­low­ing a host of tri­al flops, An­gion halts R&D work, search­es for ‘strate­gic al­ter­na­tives’

Lei Lei Wu

News Reporter

Af­ter scrap­ping a Phase II kid­ney dis­ease study last month, it ap­pears An­gion Bio­med­ica may be out of moves.

The Union­dale, NY-based biotech an­nounced Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times